Related Experiment Video
Updated: Jun 4, 2026
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Metformin-induced lactic acidosis: no one left behind
Sarah Vecchio1, Alessandro Protti
1Centro Nazionale di Informazione Tossicologica-Centro Antiveleni, IRCCS Fondazione Salvatore Maugeri, Via S. Maugeri 10, 27100 Pavia, Italy.
Critical Care (London, England)
|February 26, 2011
Summary
Metformin is generally safe, but rare cases of lactic acidosis can occur due to drug accumulation, often from kidney issues. Treatment involves supportive care and dialysis, with a surprisingly good prognosis despite severe symptoms.
Area of Science:
- Pharmacology
- Nephrology
- Critical Care Medicine
Background:
- Metformin is a widely prescribed antidiabetic medication.
- While generally safe, metformin-associated lactic acidosis (MALA) is a rare but serious adverse event.
- MALA is typically linked to drug accumulation, often secondary to renal impairment.
Purpose of the Study:
- To review the occurrence and management of metformin-induced lactic acidosis.
- To highlight the importance of patient selection and risk factor identification.
- To discuss treatment strategies and prognosis for MALA.
Main Methods:
- Literature review of reported metformin-induced lactic acidosis cases.
- Analysis of clinical presentation, risk factors, and treatment outcomes.
- Focus on cases where metformin accumulation due to renal failure was the primary cause.
Main Results:
- Metformin-induced lactic acidosis is rare but associated with significant morbidity.
- Renal failure is the most common risk factor leading to metformin accumulation.
- Treatment involving supportive care and renal replacement therapy yields a good prognosis.
Conclusions:
- Metformin can be safely used in appropriately selected patients.
- Vigilance for lactic acidosis, especially in patients with renal impairment, is crucial.
- Prompt treatment, including drug removal via dialysis, improves outcomes in MALA.
More Related Videos
Related Concept Videos
01:25Diabetic Ketoacidosis l: Introduction
DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...
01:22Diabetic Ketoacidosis ll: Pathophysiology
Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...